Engineering parvalbumin for the heart: optimizing the Mg\textsuperscript{2+} binding properties of rat β-parvalbumin

Jianchao Zhang, Vikram Shettigar, George C. Zhang, Daniel G. Kindell, Xiaotong Liu, Joseph J. López, Vinatham Yerrimuni, Grace A. Davis and Jonathan P. Davis*

Department of Physiology and Cell Biology, The Ohio State University, Columbus, OH, USA

Parvalbumin (PV), an EF-hand protein family member, is a delayed calcium buffer that exchanges magnesium for calcium to facilitate fast skeletal muscle relaxation. Genetic approaches that express parvalbumin in the heart also enhance relaxation and show promise of being therapeutic against various cardiac diseases where relaxation is compromised. Unfortunately, skeletal muscle PVs have very slow rates of Ca\textsuperscript{2+} dissociation and are prone to becoming saturated with Ca\textsuperscript{2+}, eventually losing their buffering capability within the constantly beating heart. In order for PV to have a more therapeutic potential in the heart, a PV with faster rates of calcium dissociation and high Mg\textsuperscript{2+} affinity is needed. We demonstrate that at 35°C, rat β-PV has an ~30-fold faster rate of Ca\textsuperscript{2+} dissociation compared to rat skeletal muscle α-PV, and still possesses a physiologically relevant Ca\textsuperscript{2+} affinity (~100 nM). However, rat β-PV will not be a delayed Ca\textsuperscript{2+} buffer since its Mg\textsuperscript{2+} affinity is too low (~1 mM). We have engineered two mutations into rat β-PV, S55D and E62D, when observed alone increase Mg\textsuperscript{2+} affinity up to fivefold, but when combined increase Mg\textsuperscript{2+} affinity ~13-fold, well within a physiologically relevant affinity. Furthermore, the Mg\textsuperscript{2+} dissociation rate (172/s) from the engineered S55D, E62D PV is slow enough for delayed Ca\textsuperscript{2+} buffering. Additionally, the engineered PV retains a high Ca\textsuperscript{2+} affinity (132 nM) and fast rate of Ca\textsuperscript{2+} dissociation (64/s). These PV design strategies hold promise for the development of new therapies to remediate relaxation abnormalities in different heart diseases and heart failure.

Keywords: parvalbumin, relaxation, calcium, magnesium

INTRODUCTION

Diastolic dysfunction, the inability of the heart to properly relax, is a hallmark of many heart diseases and heart failure (Periasamy and Janssen, 2008). During this condition, it is generally thought that the cardiac myocyte loses the ability to efficiently and effectively manage intracellular Ca\textsuperscript{2+}, prolonging relaxation (Bers, 2006; van der Velden, 2011). Attempts to restore the Ca\textsuperscript{2+} balance show promise of alleviating the symptoms of this debilitating cardiac condition (Wang et al., 2009; Gwathmey et al., 2011; McCauley and Wehrens, 2011; Rohde et al., 2011).

One novel approach to counter the Ca\textsuperscript{2+} imbalance has been borrowed from a specialized mechanism in fast twitch skeletal muscle that aids in relaxation. This mechanism utilizes a protein called parvalbumin (PV) to achieve faster relaxation in combination with the sarcoplasmic reticulum Ca\textsuperscript{2+} ATPase (Hou et al., 1993). PV is a small, cytosolic Ca\textsuperscript{2+} buffering protein found in high concentrations within fast-relaxing muscle ranging in species from fish to humans (Heizmann et al., 1982; Wilwert et al., 2006). Skeletal muscle PV binds both Ca\textsuperscript{2+} and Mg\textsuperscript{2+} competitively, typically with a Ca\textsuperscript{2+} affinity three to four orders of magnitude greater than Mg\textsuperscript{2+} (K\textsubscript{dCa\textsuperscript{2+}} ~ 1 to 10 nM; K\textsubscript{dMg\textsuperscript{2+}} ~ 20 to 50 μM; Pauls et al., 1993; Eberhard and Erne, 1994). In a resting muscle, the free concentration of Ca\textsuperscript{2+} is very low (~100 nM), while the free Mg\textsuperscript{2+} concentration is very high (~1 mM; Williams, 1993). Thus, in a relaxed muscle, PV is bound with Mg\textsuperscript{2+} and cannot bind Ca\textsuperscript{2+} until Mg\textsuperscript{2+} dissociates (Hou et al., 1991). The Mg\textsuperscript{2+} dissociation rate from PV is quite slow (less than 10/s) making PV a delayed Ca\textsuperscript{2+} buffer, allowing troponin C to bind Ca\textsuperscript{2+} and initiate contraction before PV exchanges Mg\textsuperscript{2+} for Ca\textsuperscript{2+} to facilitate relaxation (Hou et al., 1992). The inferred physiological Ca\textsuperscript{2+} and Mg\textsuperscript{2+} exchange rates are nearly identical to those measured biochemically (Hou et al., 1993; Jang et al., 1996; Lee et al., 2000).

Naturally, PV is not typically expressed in the heart (Sztatkowski et al., 2001). Due to its delayed Ca\textsuperscript{2+} buffer capability and ATP-independent mechanism, PV has a potential to be used therapeutically in the heart (Raake et al., 2011). In fact, in vitro and in vivo gene transfer of PV into the cardiac myocyte has been shown to increase the rate and extent of relaxation in normal and diseased states (Wang et al., 2009). However, with increasing frequency of contraction, PV loses its Ca\textsuperscript{2+} buffering potential (therefore losing its enhanced relaxing properties) due to its slow rate of Ca\textsuperscript{2+} dissociation (less than 3/s; Hou et al., 1992; Day et al., 2008). In order to recharge PV’s relaxing capability, the muscle must rest to give time for PV to re-exchange Ca\textsuperscript{2+} for Mg\textsuperscript{2+}. Unlike skeletal muscle, cardiac muscle does not have the liberty to rest for prolonged periods of time.

One potential way to overcome this inherent problem is to use a PV that has a faster rate of Ca\textsuperscript{2+} dissociation with a high affinity for Mg\textsuperscript{2+}. There are two isoforms of PV found in nature, α-PV and β-PV (Arif, 2009). Mammals utilize α-PV, while fish utilize β-PV...
in their skeletal muscle. The PVs from both mammalian and fish skeletal muscle have relatively similar cation binding properties, especially with regard to possessing slow rates of Ca\(^{2+}\) dissociation (White, 1988; Eberhard and Erne, 1994; Lee et al., 2000; Erickson and Moerland, 2006). On the other hand, mammalian β-PV, which is found in the brain, ear, placenta, and macrophages [not normally found in muscle (Belkacemi et al., 2002; Yin et al., 2006; Csillik et al., 2010)] has drastically lower affinity for both Ca\(^{2+}\) and Mg\(^{2+}\) compared to mammalian α-PV (Hapak et al., 1989). The rates of Ca\(^{2+}\) and Mg\(^{2+}\) exchange from mammalian β-PV are currently unknown and will be addressed in this manuscript. In any regard, mammalian β-PV still possesses a high enough Ca\(^{2+}\) affinity (~100 nM) to buffer Ca\(^{2+}\) in the heart. However, due to its very low Mg\(^{2+}\) affinity (greater than 1 mM), much of the PV will not be bound by Mg\(^{2+}\). In this case, mammalian β-PV will not actually be a delayed Ca\(^{2+}\) buffer and will compromise force production in the heart. Thus, we set out to engineer a higher Mg\(^{2+}\) affinity β-PV (while maintaining its Ca\(^{2+}\) affinity) that should function properly in the heart.

A great deal of work has been put into understanding the molecular mechanisms that control Ca\(^{2+}\) and Mg\(^{2+}\) binding to PV. For instance, Henzl et al. (1996) have previously shown that replacing one of the Ca\(^{2+}\) chelating residues in rat β-PV, Ser 55 with Asp, greatly increased Mg\(^{2+}\) affinity at room temperature using the flow dialysis method. In this manuscript, we have utilized this modification and a novel mutation, Glu 62 Asp, to engineer a mammalian β-PV that has appropriate affinities for both Ca\(^{2+}\) and Mg\(^{2+}\), as well as fast enough exchange kinetics, to potentially be a beneficial Ca\(^{2+}\) buffer in the constantly beating heart. This work represents the first step in designing a PV for the heart.

**MATERIALS AND METHODS**

**MATERIALS**

DEAE Sepharose™Fast Flow was purchased from GE Healthcare (Piscataway, NJ, USA). Quin-2 was purchased from Molecular Probes (Eugene, OR, USA). MOPS, Ethidium Bromide, and EGTA were purchased from Sigma Chemical Company (St. Louis, MO, USA). All other chemicals were of analytical grade.

**PROTEIN OVER-EXPRESSION, PURIFICATION, AND MUTAGENESIS**

All DNA manipulations were performed using standard molecular biology techniques (Sambrook and Russell, 1989). Plasmids containing rat α- and β-PV were generous gifts from Dr. Michael Henzl (University of Missouri). The two rat PV coding sequences were individually sub-cloned into the over-expression vector Pet3b (kindly provided by Dr. Brandon Biesiadecki, The Ohio State University) by PCR to produce Pet3b/α-PV and Pet3b/β-PV.

Conditions for purification of the two proteins were optimized based on an existing protocol with the following modifications (Hapak et al., 1989). For α-PV, the Pet3b/α-PV plasmid was transformed into BL21(DE3) bacteria (Novagen). A single colony was grown to inoculate 1 l LB/Ampicillin media and 1 mM IPTG was added after the OD\(_{600}\) of the culture was greater than 1.0. After 4 h, the cells were harvested by centrifugation. The cell pellet was resuspended in 25 ml of resuspension buffer (20 mM MOPS, 240 mM KCl, 2 mM EDTA, 1 mM DTT, pH 7.4) containing 1 mM PMSF and the cells were broken by sonication. The cell lysate was clarified by centrifugation. Mg\(^{2+}\) and Ca\(^{2+}\) were then added to the lysate to a final concentration of 10 and 1 mM, respectively. Ammonium sulfate (AMS) fractionation to 100% was performed on the cell lysate. The supernatant was dialyzed against three, 4 l of buffer A (1 mM MOPS, 1 mM EDTA, pH 7.4).

A great deal of work has been put into understanding the molecular mechanisms that control Ca\(^{2+}\) and Mg\(^{2+}\) binding to PV. For instance, Henzl et al. (1996) have previously shown that replacing one of the Ca\(^{2+}\) chelating residues in rat β-PV, Ser 55 with Asp, greatly increased Mg\(^{2+}\) affinity at room temperature using the flow dialysis method. In this manuscript, we have utilized this modification and a novel mutation, Glu 62 Asp, to engineer a mammalian β-PV that has appropriate affinities for both Ca\(^{2+}\) and Mg\(^{2+}\), as well as fast enough exchange kinetics, to potentially be a beneficial Ca\(^{2+}\) buffer in the constantly beating heart. This work represents the first step in designing a PV for the heart.

**DETERMINATION OF Ca\(^{2+}\) AND Mg\(^{2+}\) AFFINITIES**

All steady-state fluorescence measurements were performed using a Perkin-Elmer LS55B Spectrofluorimeter at 35 °C. This temperature was utilized for direct comparison to previous studies and is very close to that of mammalian body temperature (Eberhard and Erne, 1994). Ca\(^{2+}\) and Mg\(^{2+}\) titrations were performed by adding microliter amounts of CaCl\(_2\) or MgCl\(_2\) to 2 ml of the proteins.
(1 μM) in 200 mM MOPS, 150 mM KCl, 4 mM EGTA, 1 mM DTT, pH 7.0 with constant stirring. The [Ca²⁺]free and [Mg²⁺]free at 35°C were calculated using the computer program EGCA02 developed by Robertson and Potter (1984). Trp fluorescence was excited at 295 nm and measured at 330 nm. The Ca²⁺ and Mg²⁺ affinities are reported as dissociation constants \([K_d(Ca)]\) and \([K_d(Mg)]\), respectively. Each \([K_d(Ca)]\) or \([K_d(Mg)]\) represents a mean of at least three titrations fit with a logistic sigmoid function mathematically equivalent to the Hill equation, as previously described (Tikunova et al., 2002).

**DETERMINATION OF Ca²⁺ AND Mg²⁺ DISSOCIATION KINETICS**

Ca²⁺ and Mg²⁺ dissociation rates were measured using an Applied Photophysics Ltd. (Leatherhead, UK) model SX.18 MV stopped-flow instrument at 35°C. Trp fluorescence was excited using a 150-W xenon arc source excited at 295 nm with emission monitored through a narrow band-pass filter centered at 334 nm (Oriel, Stratford, CT, USA). Direct Ca²⁺ dissociation rates were also measured using the fluorescent Ca²⁺ chelator Quin-2 (Tikunova et al., 2002; Davis et al., 2004). Quin-2 was excited at 330 nm with its emission monitored through a 510-nm broad band-pass interference filter (Oriel, Stratford, CT, USA). The buffer used for the stopped-flow experiments was 10 mM MOPS, 150 mM KCl, 1 mM DTT, at pH 7.0. To measure the kinetics of Ca²⁺ dissociation from PV, 10 μM Ca²⁺ was equilibrated with 5 μM protein and rapidly mixed with buffer containing 30 mM EDTA. To measure the kinetics of Mg²⁺ dissociation from PV, 500 μM Mg²⁺ and 5 mM EGTA (to remove contaminating Ca²⁺) were equilibrated with 5 μM protein and rapidly mixed with buffer containing 30 mM EDTA. For the Quin-2 studies, there was enough contaminating Ca²⁺ in the buffer to observe the Ca²⁺ dissociation rates when 6 μM protein was rapidly mixed with the buffer containing 150 μM Quin-2.

**DATA ANALYSIS AND STATISTICS**

Statistical significance was determined by ANOVA followed by a Dunnett’s post hoc t-test, using the statistical analysis software Minitab (State College, PA, USA). Two means were considered to be significantly different when the P value was <0.05. The data is shown as a mean value ± SEM.

**RESULTS**

PV is an unusually stable protein, especially in the presence of Ca²⁺ and/or Mg²⁺ (Filimonov et al., 1978). In order to simplify the purification protocol for PV, we speculated that unlike other proteins, it would not denature and precipitate in 100% saturating AMS when in the presence of Ca²⁺ and Mg²⁺. Consistent with this idea, 100% AMS saturation precipitated nearly all the bacterial proteins, leaving PV and nucleic acids in the supernatant as judged by Coomassie Brilliant Blue and Ethidium Bromide staining as can be seen in Figures 1A,B (lane 1, data shown for E62D F102W β-PV). The gel was stained with Coomassie Brilliant Blue. Lane 1: a positive control sample from rat F102W β-PV, which was characterized before the nucleic acid contamination issue was resolved. Lanes 2–15 correspond to elution fractions from 21 to 35 after the DEAE column (refer to Materials and Methods). The same SDS-PAGE from (A), but was re-stained with Ethidium Bromide and viewed with UV light (refer to Materials and Methods).

There is ample evidence that PV increases the relaxation rate of skeletal muscle (Hou et al., 1991, 1993). Gene transfer of both skeletal muscle α-PV and β-PV has been shown to do the same in cardiac myocytes (Rodenbaugh et al., 2007). However, the skeletal muscle PVs are not designed to work in a muscle that constantly contracts and relaxes and will eventually saturate with Ca²⁺ (Hou et al., 1993; Szatkowski et al., 2001). Similar to previous studies (Eberhard and Erne, 1994), Figures 2A,B demonstrate that rat skeletal muscle F102W α-PV binds Ca²⁺ with a \(K_d(Ca)\) of 1.9 ± 0.4 nM and Mg²⁺ with a \(K_d(Mg)\) of 26 ± 2 μM at 35°C (Table 1). Also similar to previous studies (Hapak et al., 1989), Figures 2A,B show that F102W β-PV binds Ca²⁺ ~49-fold weaker and Mg²⁺ ~35-fold weaker than F102W α-PV (Table 1). Although
the Ca\(^{2+}\) and Mg\(^{2+}\) affinities of F102W β-PV are within the physiological range for these cations, the Mg\(^{2+}\) affinity of F102W β-PV is too weak to be a useful delayed Ca\(^{2+}\) buffer in the heart.

In addition to their extremely high Ca\(^{2+}\) affinity, another reason why the skeletal muscle PVs saturate with Ca\(^{2+}\) upon repeated or prolonged contraction is their slow rates of Ca\(^{2+}\) dissociation (Hou et al., 1992; Day et al., 2008). Consistent with previous studies (Lee et al., 2000), Figure 3A shows that the rate of Ca\(^{2+}\) dissociation from F102W α-PV is 1.68 ± 0.01/s at 35°C. Consistent with its weaker Ca\(^{2+}\) affinity, Figure 3A shows that F102W β-PV has an ∼32-fold faster rate of Ca\(^{2+}\) dissociation compared to F102W α-PV. The Ca\(^{2+}\) dissociation rates reported by Trp were

### Table 1 | Summary of the Ca\(^{2+}\) and Mg\(^{2+}\) binding properties of the modified PVs.

| Mutated proteins | \(K_{d}(Ca)\) (nM) | \(K_{off}(Ca)\) (s) | \(K_{d}(Mg)\) (μM) | \(K_{off}(Mg)\) (s) |
|------------------|-------------------|-------------------|--------------------|-------------------|
| F102W α-PV       | 1.9 ± 0.4         | 1.68 ± 0.01       | 26 ± 2             | 3.70 ± 0.07       |
| F102W β-PV       | 93 ± 4*           | 53.1 ± 0.5*       | 914 ± 43*          | 125 ± 3*          |
| S55D, F102W β-PV | 54 ± 1*          | 36.0 ± 0.6*       | 188 ± 2*           | 267 ± 5*          |
| E62D, F102W β-PV | 78 ± 1*          | 59 ± 2*           | 349 ± 4*           | 100 ± 4*          |
| S55D, E62D, F102W β-PV | 132 ± 6*    | 64 ± 2*           | 69 ± 1*           | 172 ± 3*          |

Values marked with * are significantly different from the F102 α-PV values, whereas values marked with # are significantly different from the F102 β-PV values (\(P < 0.05\)).
nearly identical to those measured with Quin-2 (data not shown), suggesting that the change in F102W fluorescence follows cation binding. Neither the F102W nor C18S mutations affected the rates of Ca\(^{2+}\) dissociation from the PVs as measured by Quin-2 (data not shown).

One reason why skeletal muscle PV does not interfere with the initial, nearly diffusion controlled, binding of Ca\(^{2+}\) to TnC is its delayed Ca\(^{2+}\) binding due to its slow rate of Mg\(^{2+}\) dissociation (Hou et al., 1992). Similar to these findings, Figure 3B shows that Mg\(^{2+}\) dissociates from F102W \(\alpha\)-PV at 3.70 ± 0.07/s (Table 1). Consistent with its weaker Mg\(^{2+}\) affinity, Figure 3B shows that F102W \(\beta\)-PV has an ∼34-fold faster rate of Mg\(^{2+}\) dissociation compared to F102W \(\alpha\)-PV (Table 1). Thus, if F102W \(\beta\)-PV is bound by Mg\(^{2+}\), it will still have a relatively slow rate of Ca\(^{2+}\) association compared to the nearly diffusion controlled rate of Ca\(^{2+}\) binding to TnC. However, due to its low Mg\(^{2+}\) affinity, much of F102W \(\beta\)-PV would not be bound by Mg\(^{2+}\) and thus would actually not be a delayed Ca\(^{2+}\) buffer.

Previously, Henzl et al. (1996) demonstrated that the S55D mutation in rat \(\beta\)-PV modestly increased the Ca\(^{2+}\) affinity, but drastically increased the Mg\(^{2+}\) affinity of the protein. This type of EF-hand chelating residue modification is thought to make the cation binding pocket smaller and bring a negatively charged ligand closer to the bound cation (Davis et al., 2002). Consistent with the previous findings and theory, Figure 4A shows that the S55D mutation in F102W \(\beta\)-PV increased the Ca\(^{2+}\) affinity ∼1.7-fold (Table 1). Figure 4B demonstrates that the S55D mutation in F102W \(\beta\)-PV also slowed the rate of Ca\(^{2+}\) dissociation ∼1.5-fold (Table 1). Similarly, the S55D mutation increased the Mg\(^{2+}\) affinity of F102W \(\beta\)-PV ∼fivefold (Figure 4C; Table 1), but also increased the rate of Mg\(^{2+}\) dissociation ∼twofold (Figure 4D; Table 1). Thus, the S55D mutation begins to bring the Mg\(^{2+}\) affinity of rat \(\beta\)-PV within a physiological range to make it a delayed Ca\(^{2+}\) buffer.

The EF-hand \(\sim Z\) chelating residue is primarily Glu, but is Asp in the sarcoplasmic calcium-binding protein from Nereis diversicolor (Vijay-Kumar and Cook, 1992). This particular EF-hand has a smaller cation binding pocket more preferable for Mg\(^{2+}\) binding. Consistent with this idea substitution of the \(\sim Z\) chelating ligand from Glu to Asp in carp \(\beta\)-PV increased Mg\(^{2+}\) affinity ∼10-fold, but also decreased the Ca\(^{2+}\) affinity ∼100-fold (Cates et al., 1999). We speculated that if we mutated the \(\sim Z\) Glu at position 62 with Asp we might increase the Mg\(^{2+}\) affinity of rat \(\beta\)-PV without influencing Ca\(^{2+}\) binding since the rat \(\beta\)-PV already has a weaker Ca\(^{2+}\) affinity. Consistent with this idea, the E62D mutation in F102W \(\beta\)-PV actually modestly increased the Ca\(^{2+}\) affinity ∼1.2-fold (Figure 5A; Table 1) and slightly increased the Ca\(^{2+}\) dissociation rate ∼1.1-fold (Figure 5B; Table 1). Significantly, fluorescence is shown as a function of \(\sim \log (\text{Mg}^{2+})\) (\(\log (M)\)) for S55D, F102W \(\beta\)-PV. (A) The Ca\(^{2+}\) dependent increase in Trp fluorescence is shown as a function of \(\sim \log (\text{Ca}^{2+})\) (\(p\text{Ca}\)) for S55D, F102W \(\beta\)-PV. (B) The time course of Trp fluorescence is shown as EDTA rapidly chelates Ca\(^{2+}\) causing dissociation of Ca\(^{2+}\) from S55D, F102W \(\beta\)-PV. (C) The Mg\(^{2+}\) dependent increase in Trp fluorescence is shown as a function of \(\sim \log (\text{Mg}^{2+})\) (\(p\text{Mg}\)) for S55D, F102W \(\beta\)-PV. (D) The time course of Trp fluorescence is shown as EDTA rapidly chelates Mg\(^{2+}\) causing dissociation of Mg\(^{2+}\) from S55D, F102W \(\beta\)-PV. All the measurements were performed as previously mentioned in the legends of Figures 2 and 3.
the E62D mutation increased the Mg\(^{2+}\) affinity of F102W β-PV ∼threefold (Figure 5C; Table 1), and decreased the rate of Mg\(^{2+}\) dissociation ∼1.3-fold (Figure 5D; Table 1). Thus, the E62D mutation increases the Mg\(^{2+}\) affinity of β-PV (without drastically altering the Ca\(^{2+}\) binding properties) and maintains a relatively slow rate of Mg\(^{2+}\) dissociation.

Since the S55D and E62D mutations are thought to increase Mg\(^{2+}\) affinity through different mechanisms (and have little impact on Ca\(^{2+}\) binding), we speculated that the combination of these two mutations might be additive on Mg\(^{2+}\) affinity. Consistent with this idea, Figures 6A,B show that the double mutation S55D, E62D had a minor effect on the Ca\(^{2+}\) affinity or dissociation rate compared to F102W β-PV (∼1.4-fold, Table 1). Furthermore, the double mutation increased the Mg\(^{2+}\) affinity ∼13-fold with a minor effect on the rate of Mg\(^{2+}\) dissociation (∼1.4-fold increase) as compared to F102W β-PV (Figures 6C,D; Table 1). Thus, the double mutation actually had a multiplicative effect of the two single mutations on the Mg\(^{2+}\) binding properties of F102W β-PV. Thus, the S55D, E62D, F102W β-PV now has Ca\(^{2+}\) and Mg\(^{2+}\) sensitivities and kinetics that should make it an ideal Ca\(^{2+}\) buffering protein for the heart.

**DISCUSSION**

It is clear that PV functions in skeletal muscle as a delayed Ca\(^{2+}\) buffer to temporarily aid relaxation (Hou et al., 1991). Metzger and co-workers have been the pioneers in studying the potential therapeutic value of using native PVs to help relax cardiac muscle (Rodenbaugh et al., 2007). They have clearly shown the proof of principle that PV can increase the rate and extent of relaxation in healthy and diseased cardiac myocytes *in vitro* and *in vivo*, as well as in small and large animal models (Wang et al., 2009). However, the PVs used to date (skeletal muscle rat α-PV and carp β-PV) have similarly slow rates of Ca\(^{2+}\) dissociation and are prone to Ca\(^{2+}\) saturation with repeated contractions, especially at high frequencies of contraction (Szatkowski et al., 2001). These studies strongly suggested that a different PV with modified Mg\(^{2+}\) and/or Ca\(^{2+}\) affinities would be needed to work in the heart. To achieve this goal, we could either explore additional existing PVs with more appropriate cation binding properties or re-engineer an existing well-studied PV.

There are four intrinsic factors of PV that must be considered in order for PV to work in the heart, these include the: Mg\(^{2+}\) affinity, Mg\(^{2+}\) dissociation rate, Ca\(^{2+}\) affinity, and Ca\(^{2+}\) dissociation rate. It is not entirely clear what properties an ideal PV for the heart should possess. Potentially, one could theoretically determine an ideal PV for the heart if there were a reliable mathematical model for cardiac muscle contraction and relaxation (Trayanova and Rice, 2011). In any regard, it should be a delayed Ca\(^{2+}\) buffer, in that it binds Mg\(^{2+}\) with an affinity at least three times lower than its physiological concentration, to ensure there is little to no
unbound PV available to rapidly chelate Ca\(^{2+}\). The Mg\(^{2+}\) dissociation rate must also be substantially slower than the rate of Ca\(^{2+}\) binding to TnC, so that the PV is a delayed Ca\(^{2+}\) buffer and will not interfere with force production. The Ca\(^{2+}\) affinity should be high enough so that it is able to out-compete Mg\(^{2+}\) binding during the relaxation phase of the muscle, but not so high that Mg\(^{2+}\) cannot out-compete Ca\(^{2+}\) binding during the resting periods between beats. Finally, the Ca\(^{2+}\) dissociation rate must be fast enough to allow the PV to continuously buffer Ca\(^{2+}\) effectively on a beat-to-beat basis, without becoming saturated with Ca\(^{2+}\). To the best of our knowledge, there is no naturally occurring PV that meets these requirements, but this does not mean one does not exist.

There are hundreds of unique PV sequences in the protein databases that are found in species that live in very diverse climates and environments. Unfortunately, there is no algorithm that can predict the Ca\(^{2+}\) or Mg\(^{2+}\) binding properties of an EF-hand protein based on its protein sequence. Additionally, there are extremely diverse skeletal muscles in these various species that utilize PV to help aid relaxation, some of which can contract and relax over 100 Hz, such as the toadfish swim bladder (yet, for only brief periods of time; Tikunov and Rome, 2009). It is clear from the steady-state sensitivities of temperate and cold-adapted fish, that their PV isoforms are also adapted to function similarly only at their native temperature (Erickson and Moerland, 2006). One of these PVs might have properties that will work in the heart. However, only a small subset of PVs have been characterized for their steady-state Ca\(^{2+}\) and Mg\(^{2+}\) binding properties, and only a handful of these have had their Ca\(^{2+}\) and Mg\(^{2+}\) kinetics measured. So far, all of the characterized PVs have very slow Ca\(^{2+}\) dissociation rates (Ogawa and Tanokura, 1986; Permyakov et al., 1987; White, 1988; Hou et al., 1992; Lee et al., 2000). Therefore, it may take a long time and great effort to find an appropriate natural PV that would work in the heart.

Another way to obtain a PV that might function appropriately in the heart is to re-engineer an existing PV. We have a great deal of experience designing mutations in other EF-hand Ca\(^{2+}\) binding proteins, including calmodulin, cardiac TnC and skeletal TnC, that alter both the steady-state and kinetics of Ca\(^{2+}\) and Mg\(^{2+}\) binding (Tikunova et al., 2001, 2002; Davis et al., 2002, 2004; Tikunova and Davis, 2004). In this manuscript we chose to re-engineer rat β-PV. The reasons for this choice are that rat β-PV has: (1) an intrinsically lower Ca\(^{2+}\) affinity than the skeletal muscle PVs (Hapak et al., 1989), but still within the physiological range of the heart; (2) a more rapid rate of Ca\(^{2+}\) dissociation than the skeletal muscle PVs (shown in this manuscript); (3) a relatively slow rate of Mg\(^{2+}\) dissociation (shown in this manuscript) so that it will be a delayed Ca\(^{2+}\) buffer; and (4) a great
deal of work has previously been performed on understanding its Ca\textsuperscript{2+} and Mg\textsuperscript{2+} sensitivities (Hapak et al., 1989; Henzl et al., 1996). As we mentioned above, the down side to using rat \(\beta\)-PV directly in the heart is its extremely low Mg\textsuperscript{2+} affinity (Hapak et al., 1989). However, we have shown in this manuscript that this problem can be overcome by rationally designed mutagenesis of rat \(\beta\)-PV.

Although this work represents the first step in designing a PV for the heart, the only way to know for certain that we have designed an appropriate PV for the heart will be to use gene transfer techniques to express this engineered PV in the heart. Studies are currently being designed to approach this goal. For these studies to be successful, not only the cation binding properties, but also the concentration of the PV must be considered (Day et al., 2008). Additional approaches are also underway in our lab to further refine the engineered rat \(\beta\)-PV (further slowing the Mg\textsuperscript{2+} dissociation rate), and design a synthetic PV based on TnC. These engineered PVs hold promise for the development of new therapies to remediate relaxation abnormalities in different heart diseases and heart failure.

ACKNOWLEDGMENTS

This research was funded, in part, by NIH grant HL09186 to Jonathan P. Davis.
Trayanova, N. A., and Rice, J. J. (2011). Cardiac electromechanical models: from cell to organ. Front. Physiol. 2:43. doi:10.3389/fphys.2011.00043

van der Velden, J. (2011). Diastolic myofilament dysfunction in the failing human heart. Pflugers Arch. 462, 155–163.

Vijay-Kumar, S., and Cook, W. J. (1992). Structure of a sarcoplasmic calcium-binding protein from Nereis diversicolor refined at 2.0 Å resolution. J. Mol. Biol. 224, 413–426.

Wang, W., Martindale, J., and Metzger, J. M. (2009). Parvalbumin: targeting calcium handling in cardiac diastolic dysfunction. Gen. Physiol. Biophys. 28, F3–F6.

White, H. D. (1988). Kinetic mechanism of calcium binding to whitewing parvalbumin. Biochemistry 27, 3357–3365.

Williams, R. J. P. (1993). Magnesium and the Cell. London: Academic Press Ltd.

Wilwert, J. L., Madhoun, N. M., and Coughlin, D. J. (2006). Parvalbumin correlates with relaxation rate in the swimming muscle of sheepshead and kingfish. J. Exp. Biol. 209, 227–237.

Yin, Y., Henzl, M. T., Lorber, B., Nakazawa, T., Thomas, T. T., Jiang, F., Langer, R., and Benowitz, L. I. (2006). Oncomodulin is a macrophage-derived signal for axon regeneration in retinal ganglion cells. Nat. Neurosci. 9, 843–852.

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 11 September 2011; paper pending published: 27 September 2011; accepted: 10 October 2011; published online: 31 October 2011.

Citation: Zhang J, Shettigar V, Zhang GC, Kindell DG, Liu X, López JJ, Yerrimuni V, Davis GA and Davis JP (2011) Engineering parvalbumin for the heart: optimizing the Mg2+ binding properties of rat β-parvalbumin. Front. Physiol. 2:77. doi: 10.3389/fphys.2011.00077

This article was submitted to Frontiers in Striated Muscle Physiology, a specialty of Frontiers in Physiology.

Copyright © 2011 Zhang, Shettigar, Zhang, Kindell, Liu, López, Yerrimuni, Davis and Davis. This is an open-access article subject to a non-exclusive license between the authors and Frontiers Media SA, which permits use, distribution and reproduction in other forums, provided the original authors and source are credited and other Frontiers conditions are complied with.